The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. East Asian Americans are ...

1. Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for Enhertu. Roche. News release. January 31 ...

Enhertu was discovered by Daiichi Sankyo and is being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. HER2 is a receptor protein that accelerates the growth of cancer cells.

Beyond logos, create business cards, social media kits, favicons, and more. Download high-resolution PNG, JPEG, and vector files, and get brand guidelines for fonts and colors. Make unlimited changes ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

On January 27, the Food and Drug Administration (FDA) expanded the approval of Enhertu (fam-trastuzumab deruxtecan) to cover people with hormone-positive, HER2-ultralow advanced breast cancer ...

UN Women Regional Director for Asia and the Pacific, Christine Arab, concluded a four-day visit to Papua New Guinea (PNG), reaffirming the organization’s commitment to supporting the Government of PNG ...